AI PRICE FORECAST
REGN Stock Forecast & AI Price Prediction
Regeneron Pharmaceuticals · Healthcare · Biotechnology
REGN live signal snapshot
REGN last traded at $959.41, up 4.73% on the session, trading 3.3% below its 52-week high of $991.73 and 62.2% above its 52-week low of $591.52. Stock Pulse 247's AI model currently rates REGN a BUY, at 69% model confidence. Short-term moving averages are mixed right now, without a clean bullish or bearish stack forming yet. The model's one-month path points toward roughly $990.03 (3.2% from here).
On the 14-day relative strength index, REGN reads 75.0, above the 70 line traders treat as overbought, so a breather would not be unusual. Its MACD line is above its signal line with a positive histogram (6.92) — upward momentum is accelerating. With the 50-day average at $811.95, 9.0% over the 200-day's $744.87, the longer-term trend structure remains positive.
The average 12-month target from 27 Wall Street analysts is $977.93 (range $812.00–$1175.00) — 1.9% upside from where REGN trades now. The current recommendation trend leans bullish: 19 Buy/Strong Buy ratings vs 0 Sell/Strong Sell (and 9 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive REGN dashboard for numbers updated throughout today's session.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. (REGN) is a biotechnology company in the healthcare sector, headquartered in Tarrytown, NY, United States. Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. It has a market value of about $99.2 billion and roughly 15,410 full-time employees. With a beta of 0.1, the stock has historically moved less than the overall market.
REGN performance vs. the market
Since the start of 2026 the stock has risen 24.3%, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). On a one-year view it is up 46.5%, 35.0 points better than the S&P 500. The last month (+27.4%) continues the three-month advance (+19.0%).
| Period | REGN | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +27.4% | +11.4% | −2.3% |
| 3 months | +19.0% | +12.2% | −2.3% |
| Year to date | +24.3% | +22.1% | +11.4% |
| 1 year | +46.5% | +28.3% | +11.5% |
Regeneron Pharmaceuticals financials at a glance
In the quarter ended Sep 30, 2026, Regeneron Pharmaceuticals reported revenue of $5.1 billion and net income of $1.9 billion (a 38.1% net margin). Revenue was up 36.3% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 21.2 on trailing earnings of $45.24 per share. Trailing free cash flow was $2.6 billion, and total debt equals 8% of shareholders' equity.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Sep 30, 2026 | $5.1B | $1.9B |
| Jun 30, 2026 | $4.3B | $1.3B |
| Mar 31, 2026 | $3.6B | $727M |
| Dec 31, 2025 | $3.9B | $845M |
REGN vs. its peers
Against 5 of its largest healthcare peers, REGN's +24.3% year-to-date return beats 1 of them. The strongest of the group this year is Merck & Co. (MRK, +39.8%).
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| Regeneron Pharmaceuticals (REGN) | $959.41 | +24.3% | 21.2 | BUY |
| Vertex Pharmaceuticals (VRTX) | $547.03 | +20.7% | 35.2 | BUY |
| Eli Lilly and (LLY) | $1,437.29 | +33.7% | 46.7 | BUY |
| Johnson & Johnson (JNJ) | $280.41 | +35.5% | 42.6 | BUY |
| AbbVie (ABBV) | $294.98 | +29.1% | 50.7 | BUY |
| Merck & Co. (MRK) | $147.18 | +39.8% | 148.7 | HOLD |
REGN stock: common questions
What is the REGN stock price target?
27 Wall Street analysts put the average 12-month target at $977.93, in a range of $812.00–$1175.00, versus a recent price of $959.41. Stock Pulse 247's model projects about $990.03 over the next month.
Is REGN a buy right now?
Our AI model currently rates REGN a BUY at 69% confidence. Among analysts, 19 rate it Buy or Strong Buy, 9 Hold and 0 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has REGN stock performed this year?
Since the start of 2026 the stock has risen 24.3%, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). On a one-year view it is up 46.5%, 35.0 points better than the S&P 500. The last month (+27.4%) continues the three-month advance (+19.0%).
What is REGN's 52-week high and low?
REGN has traded between $591.52 and $991.73 over the past 52 weeks; at $959.41 it is 3.3% below its 52-week high of $991.73 and 62.2% above its 52-week low of $591.52.
What sector is REGN in, and who are its peers?
REGN is in the healthcare sector (biotechnology). Its largest peers on Stock Pulse 247 include Vertex Pharmaceuticals (VRTX), Eli Lilly and (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV).
How accurate is the REGN forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines REGN's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.